PureTech Health plc
Business
PureTech Health plc develops and advances biopharmaceutical product candidates using a diversified hub-and-spoke model focused on translating validated biology into new therapeutics. It offers discovery, preclinical and clinical development of drug and biologic candidates (including programs such as LYT-100 and LYT-200), and supports Founded Entities that advance complementary technologies. Key business segments consist of internal programs and investments/operations of its Founded Entities, together with licensing and collaboration activities. Its operations target global regulatory markets, with development and potential commercialization activities in the United States, European Union, the United Kingdom and other international jurisdictions via partners and collaborators.
Summary from filing dated 2025-04-30
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-110.08M |
| Total assets | $534.71M |
| Total liabilities | $229.03M |
| Stockholders' equity | — |
| Operating cash flow | — |